T-cell profiling and the immunodiagnosis of latent tuberculosis infection in patients with inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 20, Issue 2, 2014, Pages 329-338

  Arias Guillén, Miguel ^a   Riestra, Sabino ^a   De Francisco, Ruth ^a   Palacios, Juan José ^a   Belda, José ^b   Escalante, Patricio ^c   Pérez Martínez, Isabel ^a   Molinos, Luis M ^d   Garcia Clemente, Marta ^a   Pando Sandoval, Ana ^a   Rodrigo, Luis ^a   Prieto, Amador ^a   Martínez Camblor, Pablo ^a   Losada, Ana ^a   Casan, Pere ^a  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b Hospital Arnau de Villanova   (Spain)

^c MAYO CLINIC   (United States)

^d NONE

Author keywords

Immunodiagnosis; Inflammatory bowel diseases; Interferon gamma release assays; Latent tuberculosis infection; T cell profiling; Tuberculin skin test

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY BOWEL DISEASE; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS TEST KIT; PRIORITY JOURNAL; PROSPECTIVE STUDY; SERODIAGNOSIS; T LYMPHOCYTE; T LYMPHOCYTE PROFILING; T LYMPHOCYTE SUBPOPULATION; THORAX RADIOGRAPHY; COMPLICATION; DIFFERENTIAL DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; IMMUNOLOGICAL PROCEDURES; IMMUNOLOGY; INCIDENCE; INFLAMMATORY BOWEL DISEASES; INNATE IMMUNITY; MASS SCREENING; PREVALENCE; PROCEDURES; RISK FACTOR; SPAIN;

ADULT; DIAGNOSIS, DIFFERENTIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC TESTS; INCIDENCE; INFLAMMATORY BOWEL DISEASES; LATENT TUBERCULOSIS; LYMPHOCYTE COUNT; MALE; MASS SCREENING; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; RISK FACTORS; SPAIN; T-LYMPHOCYTE SUBSETS;

EID: 84893714967     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/01.MIB.0000438429.38423.62     Document Type: Article

References (43)

1. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor a-neutralizing agent. N Engl J Med. 2001; 345:1098-1104.
2. Solovic I, Sester M, Gomez-Reino JJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J. 2010;36:1185-1206.
3. Rahier JF, Ben-Horin S, Chowers Y, et al. European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohn's Colitis. 2009;3:47-91.
4. González-Martín J, García-García JM, Anibarro L, et al. Documento de consenso sobre diagnóstico, tratamiento y prevención de la tuberculosis [in Spanish]. Arch Bronconeumol. 2010;46:255-274.
5. British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax. 2005;60:800-805.
6. Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum. 2005;52:1766-1772.
7. Gómez-Reino JJ, Carmona L, Descalzo MA, et al. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum. 2007;57: 756-761.
8. Reenaers C, Belaiche J, Louis E. Should patients under long-term anti- TNF therapies be followed for tuberculosis contamination? Inflamm Bowel Dis. 2010;16:1271-1272.
9. Jáuregui-Amezaga A, Turon F, Ordás I, et al. Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening. J Crohn's Colitis. 2013;7:208-212.
10. Mow WS, Abreu-Martin MT, Papadakis KA, et al. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol. 2004;2:309-313.
11. van Zyl-Smit RN, Pai M, Peprah K, et al. Within- subject variability and boosting of T cell IFN-{gamma} responses following tuberculin skin testing. Am J Respir Crit Care Med. 2009;180:49-58.
12. Belard E, Semb S, Ruhwald M, et al. Prednisolone treatment affects the performance of the QuantiFERON gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection. Inflamm Bowel Dis. 2011;17:2340-2349.
13. del Tedesco E, Roblin X, Laharie D, et al. Does anti-TNF Therapy influence the performance of Mycobacterium tuberculosis antigen-specific interferon-gamma assays? A French multicenter experience. Inflamm Bowel Dis. 2011;17:1824.
14. Butera O, Chiacchio T, Carrara S, et al. New tools for detecting latent tuberculosis infection: evaluation of RD1-specific long-term response. BMC Infect Dis. 2009;9:182.
15. Mazurek GH, Jereb J, Vernon A, et al. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection-United States, 2010. MMWR. 2010;59:1-25.
16. Shahidi N, Fu YN, Qian H. Performance of interferon-gamma release assays in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2012;18:2034-2042.
17. Bocchino M, Matarese A, Bellofiore B, et al. Performance of two commercial blood IFN-gamma release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-alpha treatment. Eur J Clin Microbiol Infect Dis. 2008;27:907-913.
18. Martin J, Walsh C, Gibbs A, et al. Comparison of interferon-gammarelease assays and conventional screening tests before tumour necrosis factor-alpha blockade in patients with inflammatory arthritis. Ann Rheum Dis. 2010;69:181-185.
19. Schoepfer AM, Flogerzi B, Fallegger S, et al. Comparison of interferongamma release assay versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease. Am J Gastroenterol. 2008;103: 2799-2806.
20. Papay P, Eser A, Winkler S, et al. Factors impacting the results of interferon- gamma release assay and tuberculin skin test in routine screening for latent tuberculosis in patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2011;17:84-90.
21. Mariette X, Baron G, Tubach F, et al. Influence of replacing tuberculin skin test with ex vivo interferon g release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy. Ann Rheum Dis. 2012;71:1783-1790.
22. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989;170:2-6.
23. López-San Román A, Obrador A, Fortún J, et al. Recomendaciones sobre tuberculosis y tratamiento de la enfermedad infamatoria intestinal con infiximab. Actualización 2006 [in Spanish]. Gastroenterol Hepatol. 2006;29:81-84.
24. Zabana Y, Domènech E, San Román AL, et al. Tuberculous chemoprophylaxis requirements and safety in inflammatory bowel disease patients prior to anti-TNF therapy. Inflamm Bowel Dis. 2008;14:1387-1391.
25. Farhat M, Greenaway C, Pai M, et al. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis. 2006;10:1192-1204.
26. Hsu KH. Tuberculin reaction in children treated with isoniazid. Am J Dis Child. 1983;137:1090-1092.
27. Chee CB, KhinMar KW, Gan SH, et al. Tuberculosis treatment effect on T-cell interferon-gamma responses to Mycobacterium tuberculosis-specific antigens. Eur Respir J. 2010;36:355-361.
28. Pollock NR, Kashino SS, Napolitano DR, et al. Evaluation of the effect of treatment of latent tuberculosis infection on QuantiFERON-TB gold assay results. Infect Control Hosp Epidemiol. 2009;30:392-395.
29. Mack U, Migliori GB, Sester M, et al. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J. 2009;33:956-973.
30. Leyten EM, Arend SM, Prins C, et al. Discrepancy between Mycobacterium tuberculosis-specific interferon-gamma release assays using short versus prolonged in vitro incubation. Clin Vaccine Immunol. 2007;14: 880-885.
31. Hang NTL, Lien LT, Kobayashi N, et al. Analysis of factors lowering sensitivity of interferon-g release assay for tuberculosis. PLoS One. 2011;6:e23806.
32. Kim EY, Park MS, Kim YS, et al. Risk factors for false-negative results of QuantiFERON-TB Gold In-Tube assay in non-HIV-infected patients with culture-confirmed tuberculosis. Diagn Microbiol Infect Dis. 2011;70:324-329.
33. Kobashi Y, Shimizu H, Ohue Y, et al. False negative results of Quanti- FERON TB-2G test in patients with active tuberculosis. Jpn J Infect Dis. 2009;62:300-302.
34. Papay P, Eser A, Winkler S, et al. Predictors of indeterminate IFN-gamma release assay in screening for latent TB in inflammatory bowel diseases. Eur J Clin Invest. 2011;41:1071-1076.
35. Oni T, Gideon HP, Bangani N, et al. Risk factors associated with indeterminate gamma interferon responses in the assessment of latent tuberculosis infection in a high-incidence environment. Clin Vaccine Immunol. 2012;19:1243-1247.
36. Newport MJ, Huxley CM, Huston S, et al. A mutation in the interferon gamma-receptor gene and susceptibility to mycobacterial infection. N Engl J Med. 1996;335:1941-1949.
37. Temmerman ST, Place S, Debrie A, et al. Effector functions of heparinbinding hemagglutinin-specific CD8+ T lymphocytes in latent human tuberculosis. J Infect Dis. 2005;192:226-232.
38. Hoang TT, Nansen A, Roy S, et al. Distinct differences in the expansion and phenotype of TB10.4 specific CD8 and CD4 T cells after infection with Mycobacterium tuberculosis. PLoS One. 2009;4:e5928.
39. Martins MV, Lima MC, Duppre NC, et al. The level of PPD-specific IFNgamma- producing CD4+ T cells in the blood predicts the in vivo response to PPD. Tuberculosis (Edinb). 2007;87:202-211.
40. Rangaka MX, Wilkinson KA, Seldon R, et al. Effect of HIV-1 infection on T-cell-based and skin test detection of tuberculosis infection. Am J Respir Crit Care Med. 2007;175:514-520.
41. Luetkemeyer AF, Charlebois ED, Flores LL, et al. Comparison of an interferon-gamma release assay with tuberculin skin testing in HIVinfected individuals. Am J Respir Crit Care Med. 2007;175:737-742.
42. Raby E, Moyo M, Devendra A, et al. The effects of HIV on the sensitivity of a whole blood IFN-gamma release assay in Zambian adults with active tuberculosis. PLoS One. 2008;3:e2489.
43. Ariga H, Nagai H, Kurashima A, et al. Stratified threshold values of QuantiFERON assay for diagnosing tuberculosis infection in immunocompromised populations. Tuberc Res Treat. 2011;2011:940642.